130 related articles for article (PubMed ID: 38908549)
1. Real-world effectiveness of imeglimin in patients with type 2 diabetes: A retrospective longitudinal study in Japan.
Katsuyama H; Hakoshima M; Heshiki T; Iida S; Adachi H; Yanai H
Diabetes Res Clin Pract; 2024 Jun; 213():111752. PubMed ID: 38908549
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of clinical glycemic control markers treated with imeglimin and its effect on erythrocytes in patients with type 2 diabetes mellitus: study protocol of a single-arm, open-label, prospective, exploratory trial.
Osonoi T; Shirabe S; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Pharmacol; 2023; 14():1205021. PubMed ID: 37351507
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of imeglimin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.
Abdelhaleem IA; Salamah HM; Alsabbagh FA; Eid AM; Hussien HM; Mohamed NI; Ebada MA
Diabetes Metab Syndr; 2021; 15(6):102323. PubMed ID: 34717136
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-Like Peptide-1 Receptor Agonist Utilization in Type 2 Diabetes in Japan: A Retrospective Database Analysis (JDDM 57).
Ishigaki Y; Strizek A; Aranishi T; Arai N; Imaoka T; Cai Z; Maegawa H
Diabetes Ther; 2021 Jan; 12(1):345-361. PubMed ID: 33300091
[TBL] [Abstract][Full Text] [Related]
5. Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Nomoto H; Takahashi A; Nakamura A; Kurihara H; Takeuchi J; Nagai S; Taneda S; Miya A; Kameda H; Cho KY; Miyoshi H; Atsumi T
BMJ Open Diabetes Res Care; 2022 Nov; 10(6):. PubMed ID: 36379585
[TBL] [Abstract][Full Text] [Related]
6. Long-term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52-week, open-label, multicentre phase 3 trial.
Dubourg J; Fouqueray P; Quinslot D; Grouin JM; Kaku K
Diabetes Obes Metab; 2022 Apr; 24(4):609-619. PubMed ID: 34866306
[TBL] [Abstract][Full Text] [Related]
7. [Pharmacological profile and clinical efficacy of imeglimin hydrochloride (TWYMEEG
Nagamine J
Nihon Yakurigaku Zasshi; 2023; 158(2):193-202. PubMed ID: 36858505
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Imeglimin on the Daily Glycemic Profile Evaluated by Intermittently Scanned Continuous Glucose Monitoring: Retrospective, Single-Center, Observational Study.
Oda T; Satoh M; Nagasawa K; Sasaki A; Hasegawa Y; Takebe N; Ishigaki Y
Diabetes Ther; 2022 Sep; 13(9):1635-1643. PubMed ID: 35895275
[TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imeglimin for Type 2 Diabetes in Patients Undergoing Dialysis.
Mima A
In Vivo; 2023; 37(3):1334-1338. PubMed ID: 37103109
[TBL] [Abstract][Full Text] [Related]
10. Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.
Hagi K; Nitta M; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2023 Nov; 14(11):1246-1261. PubMed ID: 37610062
[TBL] [Abstract][Full Text] [Related]
11. Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.
Ishibashi R; Hirayama K; Watanabe S; Okano K; Kuroda Y; Baba Y; Kanayama T; Ito C; Kasahara K; Aiba S; Iga R; Ohtani R; Inaba Y; Koshizaka M; Maezawa Y; Yokote K
J Diabetes Investig; 2023 Dec; 14(12):1419-1422. PubMed ID: 37715448
[TBL] [Abstract][Full Text] [Related]
12. Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study.
Uchida T; Ueno H; Konagata A; Taniguchi N; Kogo F; Nagatomo Y; Shimizu K; Yamaguchi H; Shimoda K
Diabetes Ther; 2023 Mar; 14(3):569-579. PubMed ID: 36732433
[TBL] [Abstract][Full Text] [Related]
13. Effect of patient characteristics on the efficacy and safety of imeglimin monotherapy in Japanese patients with type 2 diabetes mellitus: A post-hoc analysis of two randomized, placebo-controlled trials.
Hagi K; Kochi K; Watada H; Kaku K; Ueki K
J Diabetes Investig; 2023 Sep; 14(9):1101-1109. PubMed ID: 37264517
[TBL] [Abstract][Full Text] [Related]
14. Status of lipid control in Bangladeshi subjects with type 2 diabetes mellitus on lipid-lowering drugs: a multicenter, facility-based, cross-sectional study.
Selim S; Alam MS; Talukder SK; Kabir ML; Gaffar AJ; Kabir MA; Zarin N; Rahman S; Nabi MMU; Mustari M; Hossain MF; Raunak AIB; Hoque MA; Islam MR; Akter F; Hannan MA; Saifuddin M; Asaduzzaman M; Rahman MM; Ahammed A; Rafi MA; Hasan MJ; Kamrul-Hasan ABM
BMC Endocr Disord; 2023 Dec; 23(1):268. PubMed ID: 38053073
[TBL] [Abstract][Full Text] [Related]
15. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24-week, randomized, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Dubourg J; Ueki K; Grouin JM; Fouqueray P
Diabetes Obes Metab; 2021 Mar; 23(3):800-810. PubMed ID: 33275318
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of imeglimin add-on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double-blind, placebo-controlled phase 3 trial with a 36-week open-label extension period.
Reilhac C; Dubourg J; Thang C; Grouin JM; Fouqueray P; Watada H
Diabetes Obes Metab; 2022 May; 24(5):838-848. PubMed ID: 34984815
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Trial.
Dubourg J; Fouqueray P; Thang C; Grouin JM; Ueki K
Diabetes Care; 2021 Apr; 44(4):952-959. PubMed ID: 33574125
[TBL] [Abstract][Full Text] [Related]
19. Different doses of imeglimin for management of type 2 diabetes mellitus: a systematic review, meta-analysis, and meta-regression of randomized clinical trials.
Permana H; Soetedjo NNM; Yanto TA; Tendean M; Hariyanto TI; Suastika K
Expert Rev Endocrinol Metab; 2024; 19(1):89-98. PubMed ID: 38047423
[TBL] [Abstract][Full Text] [Related]
20. Imeglimin: the New Kid on the Block.
Shrestha SC; Gupta S
Curr Diab Rep; 2024 Jan; 24(1):13-18. PubMed ID: 38051432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]